Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zosano Pharma Corp (ZSAN)
|
Add to portfolio |
|
|
|
| Price: |
$0.52
| | Metrics |
| OS: |
4.9
|
M
| |
|
|
| Market cap: |
$2.54
|
M
| |
|
|
|
Net cash:
|
$13.5
|
M
| |
$2.76
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.8 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 2.9 |
| Revenue growth | 250.4% | | | | | -100.0% | -89.1% | -32.7% |
| Cost of goods sold | 0.8 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Gross profit | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 2.8 |
| Gross margin | -1.4% | 23.7% | | | | | 100.0% | 96.5% |
| Research and development | 21.0 | 21.6 | 25.4 | 25.5 | 20.1 | 20.5 | 20.4 | 11.0 |
| General and administrative | 10.5 | 11.2 | 11.8 | 9.4 | 8.2 | 8.2 | 6.3 | 4.4 |
| EBIT | -31.5 | -32.8 | -37.2 | -34.9 | -28.3 | -28.6 | -26.4 | -12.6 |
| EBIT margin | -4016.8% | -14624.1% | | | | | -8424.3% | -440.8% |
| Pre-tax income | -29.9 | -33.4 | -37.6 | -35.4 | -29.1 | -29.8 | -28.4 | -14.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -29.9 | -33.4 | -37.6 | -35.4 | -29.1 | -29.8 | -28.4 | -14.2 |
| Net margin | -3812.1% | -14896.9% | | | | | -9082.1% | -497.8% |
| |
| Diluted EPS | ($0.27) | ($0.49) | ($2.29) | ($3.74) | ($16.82) | ($43.36) | ($2.49) | ($2.78) |
| Shares outstanding (diluted) | 112.1 | 67.9 | 16.4 | 9.5 | 1.7 | 0.7 | 11.4 | 5.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|